NextCure, Inc. (NASDAQ:NXTC – Get Free Report) major shareholder Adar1 Capital Management, Llc acquired 7,798 shares of NextCure stock in a transaction dated Monday, July 27th. The shares were purchased at an average cost of $5.00 per share, with a total value of $38,990.00. Following the completion of the transaction, the insider directly owned 383,456 shares of the company’s stock, valued at $1,917,280. This trade represents a 2.08% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Adar1 Capital Management, Llc also recently made the following trade(s):
- On Wednesday, July 29th, Adar1 Capital Management, Llc bought 3,410 shares of NextCure stock. The stock was purchased at an average cost of $5.00 per share, for a total transaction of $17,050.00.
- On Tuesday, July 28th, Adar1 Capital Management, Llc purchased 6,400 shares of NextCure stock. The shares were purchased at an average cost of $4.95 per share, with a total value of $31,680.00.
NextCure Stock Down 7.4%
Shares of NXTC opened at $5.02 on Thursday. The stock has a market capitalization of $18.12 million, a P/E ratio of -0.29 and a beta of 1.42. NextCure, Inc. has a twelve month low of $1.55 and a twelve month high of $15.74. The company has a 50 day moving average of $3.66 and a 200-day moving average of $8.77.
Wall Street Analyst Weigh In
NXTC has been the topic of several analyst reports. Weiss Ratings cut shares of NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, July 7th. Zacks Research upgraded NextCure from a “strong sell” rating to a “hold” rating in a report on Thursday, June 11th. Wall Street Zen downgraded NextCure from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of NextCure in a research report on Wednesday, July 15th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, NextCure has a consensus rating of “Hold” and an average price target of $19.00.
Check Out Our Latest Research Report on NXTC
Hedge Funds Weigh In On NextCure
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Marshall Wace LLP bought a new stake in NextCure during the fourth quarter worth $160,000. Millennium Management LLC bought a new position in shares of NextCure in the 4th quarter valued at about $185,000. Geode Capital Management LLC increased its stake in shares of NextCure by 18.6% during the 4th quarter. Geode Capital Management LLC now owns 23,157 shares of the company’s stock worth $329,000 after purchasing an additional 3,636 shares during the last quarter. Renaissance Technologies LLC increased its stake in shares of NextCure by 18.7% during the 4th quarter. Renaissance Technologies LLC now owns 33,634 shares of the company’s stock worth $477,000 after purchasing an additional 5,300 shares during the last quarter. Finally, Boothbay Fund Management LLC bought a new stake in shares of NextCure in the 4th quarter valued at about $988,000. 42.65% of the stock is owned by institutional investors.
NextCure Company Profile
NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.
The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.
Featured Articles
- Five stocks we like better than NextCure
- Why SK hynix Could Be the Best AI Chip Stock to Buy Now
- Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters
- Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead?
- Why Bloom Energy May Be the Most Important AI Infrastructure Stock
Receive News & Ratings for NextCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NextCure and related companies with MarketBeat.com's FREE daily email newsletter.
